TXMD: TherapeuticsMD, Inc. Stock

by  •  • Comments Off on TXMD: TherapeuticsMD, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 11.65
Enterprise Value ($M) 6.60
Book Value ($M) 27.09
Book Value / Share 2.35
Price / Book 0.43
NCAV ($M) -0.30
NCAV / Share -0.03
Price / NCAV -38.31

Profitability (mra)
Return on Invested Capital (ROIC) -0.10
Return on Assets (ROA) -0.08
Return on Equity (ROE) -0.11

Liquidity (mrq)
Quick Ratio 2.03
Current Ratio 2.03

Balance Sheet (mrq) ($M)
Current Assets 12.15
Assets 39.55
Liabilities 12.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13G Clearline Capital LP

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 5,415,511 13,944,064 38.84
2025-02-20 7,322 32,975 22.20
2025-02-19 1,324 20,574 6.44
2025-02-18 5,090 27,859 18.27

(click for more detail)

Similar Companies
TSHA – Taysha Gene Therapies, Inc. TSVT – 2seventy bio, Inc.
TWST – Twist Bioscience Corporation TYRA – Tyra Biosciences, Inc.
UBX – Unity Biotechnology, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: TherapeuticsMD